San Antonio, TX, United States of America

Elzbieta Izbicka

This inventor holds 14 USPTO granted patents and 8 published patent applications, plus 3 CIPO patents and 5 EPO patents. Top assignees: New Frontier Labs, LLC, Cancer Prevention and Cure, Ltd., Osteosa Inc.. Active years: 1995-2026.

USPTO Granted Patents = 14 (Patent Applications = 8)

% Patents Active = 100.0

CIPO Patents = 3 (Patent Applications = 6)

EPO Patents = 5 (Patent Applications = 16)

Average Co-Inventor Count = 2.7

ph-index = 4

Forward Citations = 110(Granted Patents)

Company Filing History:

6 out of 6

New Frontier Labs, LLC

patents

5 out of 5

Cancer Prevention and Cure, Ltd.

Rhone-Poulenc Rorer Pharmaceuticals Inc.

patents

where one patent can have more than one assignee

Years Active: 1995-2026

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12605354 - Azelaic acid esters in the treatment or prevention of dyslipidemia and associated conditions (2026-04-21),

2. 12329735 - Azelaic acid esters in the treatment of insulin resistance (2025-06-17),

3. 11918555 - Dicarboxylic acid esters for the treatment of diseases and conditions associated with phospholipase D toxin (2024-03-05),

4. 11911358 - Dicarboxylic acid esters for inducing an analgesic effect (2024-02-27),

5. 11474104 - Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy (2022-10-18),

6. 11026912 - Azelaic acid esters in the treatment of insulin resistance (2021-06-08),

7. 10251857 - Azelaic acid esters in the treatment of insulin resistance (2019-04-09),

8. 9952220 - Methods of identification and diagnosis of lung diseases using classification systems and kits thereof (2018-04-24),

9. 9933429 - Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof (2018-04-03),

10. 8541183 - Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof (2013-09-24),

11. 7888051 - Method of identifying biomarkers in human serum indicative of pathologies of human lung tissues (2011-02-15),

12. 5656598 - Use of fibroblast growth factors to stimulate bone growth (1997-08-12),

13. 5614496 - Use of fibroblast growth factors to stimulate bone growth (1997-03-25),

14. 5408041 - Process of purifying antler-derived bone growth factors (1995-04-18),

Title: Elzbieta Izbicka: Innovator in Pharmaceutical Treatments

Introduction

Elzbieta Izbicka is a prominent inventor based in San Antonio, TX, known for her significant contributions to the field of pharmaceuticals. With a total of 13 patents to her name, she has made remarkable strides in developing innovative treatments for various medical conditions.

Latest Patents

Among her latest patents is a method for treating insulin resistance, which involves administering a pharmaceutical composition comprising diethyl azelate. This method allows for oral administration at a dosage range from about 0.1 mg/kg/day to about 10 mg/kg/day. Another notable patent focuses on dicarboxylic acid esters for treating diseases associated with phospholipase D toxin. This disclosure provides compositions and methods aimed at addressing conditions linked to PLD toxin through the administration of a dicarboxylic acid ester.

Career Highlights

Elzbieta has worked with several companies throughout her career, including Cancer Prevention and Cure, Ltd. and New Frontier Labs, LLC. Her work in these organizations has been instrumental in advancing research and development in the pharmaceutical sector.

Collaborations

Elzbieta has collaborated with notable professionals in her field, including Robert T Streeper and Sung H Baek. These partnerships have contributed to her innovative research and the successful development of her patented methods.

Conclusion

Elzbieta Izbicka's work exemplifies the impact of innovation in the pharmaceutical industry. Her dedication to developing effective treatments continues to inspire advancements in medical science.